Passive Immune-oncology Therapy (Antibody Drug Conjugate)
An Antibody Drug Conjugate (ADC) treatment for cancer that is based on Globo H, OBI-999 uses a Globo H antibody to target cancer cells of high Globo H expression. By releasing a small molecule chemotherapeutic drug through the specificity of the antibody, it directly deploys cytotoxicity therapy at the targeted cancer cells. Preliminary pharmacological studies and animal verification have already been completed, and it is currently undergoing Chemistry Manufacturing Control (CMC) planning and toxicology study design. Proposed patent applications and arrangements are also underway.